Kangstem Biotech Co., Ltd. (217730.KQ)
- Previous Close
2,435.00 - Open
2,475.00 - Bid 2,440.00 x --
- Ask 2,450.00 x --
- Day's Range
2,420.00 - 2,515.00 - 52 Week Range
1,388.00 - 3,920.00 - Volume
613,636 - Avg. Volume
371,944 - Market Cap (intraday)
136.492B - Beta (5Y Monthly) 0.66
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and platelet-derived growth factors, as well as growth and differentiation factor 11, and Fibroblast growth factor 2 for skin growth and regeneration. In addition, the company offers stem cell culture media, including KSB-3 kit, a medium for culturing the human mesenchymal stem cell; and cell freezing and thawing platform. Further, it provides pharmaceutical contract manufacturing and development services. Kangstem Biotech Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.
www.kangstem.comRecent News: 217730.KQ
View MorePerformance Overview: 217730.KQ
Trailing total returns as of 4/23/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 217730.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 217730.KQ
View MoreValuation Measures
Market Cap
136.49B
Enterprise Value
126.68B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.47
Price/Book (mrq)
3.16
Enterprise Value/Revenue
16.35
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-64.82%
Return on Assets (ttm)
-19.06%
Return on Equity (ttm)
-26.14%
Revenue (ttm)
12.77B
Net Income Avi to Common (ttm)
-10.09B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
25.82B
Total Debt/Equity (mrq)
16.03%
Levered Free Cash Flow (ttm)
-10.35B